Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 113 clinical trials
Featured trial
A trial evaluating TEPEZZA® in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

weeks (q3W) for 24 weeks in the treatment of participants with diffuse cutaneous systemic sclerosis (dcSSc).

  • 0 views
  • 20 May, 2022
  • 3 locations
Featured trial
Study to evaluate HZN-825 in patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc)

The goal is to determine the efficacy, safety and tolerability for 300 patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc) assigned to either one of 2 dose regimens of HZN-825

raynaud's syndrome
diffuse cutaneous systemic sclerosis
MRSS
rheumatism
raynaud's phenomenon
  • 0 views
  • 20 May, 2022
  • 35 locations
Featured trial
A phase 3, randomized, placebo-controlled study to assess the efficacy and safety of an investigational medication versus placebo in patients with systemic sclerosis

A phase 3, randomized, placebo-controlled study to assess the efficacy and safety of an investigational medication versus placebo in patients with systemic sclerosis

  • 1212 views
  • 23 Nov, 2020
  • 1 location
Featured trial
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 246 views
  • 25 Mar, 2021
  • 1 location
Small Bowel Motility in Patients With Systemic Sclerosis

Several studies using intestinal manometry have reported alterations in small bowel motility in patients with systemic sclerosis. Our aim is to apply endoluminal image analysis to stratify the

  • 0 views
  • 21 Mar, 2022
  • 1 location
Effect of the Use of Specific Oral Hygiene Devices on Gingival Health Among Patients With Systemic Sclerosis

Systemic sclerosis is a rare multisystem connective-tissue disorder characterized by three major pathological hallmarks: widespread fibrosis, vasculopathy and immunological abnormalities. This

vascular disease
fibrosis
  • 0 views
  • 20 Sep, 2021
  • 1 location
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential

  • 0 views
  • 25 Apr, 2022
  • 6 locations
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

Pulmonary Arterial Hypertension or PAH is a progressive condition for which there is no cure. Even with substantial pharmacologic advances in the modern treatment era, survival still remains unacceptably poor, as reported in large PAH registries. Preclinical studies suggest that the administration of allogeneic CDCs have the potential to reduce …

  • 99 views
  • 25 Mar, 2021
  • 1 location
A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 4 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 …

raynaud's syndrome
diffuse cutaneous systemic sclerosis
MRSS
rheumatism
raynaud's phenomenon
  • 2 views
  • 11 May, 2022
  • 30 locations
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

To evaluate the efficacy of MT-7117 treatment in subjects with diffuse cutaneous systemic sclerosis (dcSSc) using the American College of Rheumatology Composite Response Index in Diffuse

  • 6 views
  • 13 May, 2022
  • 40 locations